Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trimph is an Australian regenerative medicine company specializing in the development of injectable, thermo-responsive scaffolds for tissue engineering. The company's core technology, TRIMPH (Temperature-Responsive Injectable Material for Phased Healing), is a synthetic polymer that remains liquid at room temperature and transitions into a solid, porous scaffold upon injection into the body. This matrix supports the natural healing process by providing a structural environment for cell infiltration and tissue regrowth in dental, orthopedic, and aesthetic applications. Trimph's lead products, including TrimphDent and TrimphBone, offer minimally invasive solutions for bone and cartilage repair, aiming to replace or augment traditional grafting procedures. The technology is designed to be biocompatible and biodegradable, eventually being replaced by the patient's own healthy tissue.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Trimph Technology.